IKBKB reduces huntingtin aggregation by phosphorylating serine 13 via a non-canonical IKK pathway

N-terminal phosphorylation at residues T3 and S13 is believed to have important beneficial implications for the biological and pathological properties of mutant huntingtin, where IKBKB was identified as a candidate regulator of huntingtin N-terminal phosphorylation. The paucity of mechanistic information on IKK pathways, together with the lack of sensitive methods to quantify endogenous huntingtin phosphorylation, prevented detailed study of the role of IKBKB in Huntington’s disease. Using novel ultrasensitive assays, we demonstrate that IKBKB can regulate endogenous S13 huntingtin phosphorylation in a manner dependent on its kinase activity and known regulators. We found that the ability of IKBKB to phosphorylate endogenous huntingtin S13 is mediated through a non-canonical IRF3-mediated IKK-pathway, distinct from the established involvement of IKBKB in mutant huntingtin’s pathological mechanisms mediated via the canonical pathway. Furthermore, increased huntingtin S13 phosphorylation by IKBKB resulted in decreased aggregation of mutant huntingtin in cells, again dependent on its kinase activity. These findings point to a non-canonical IKK-pathway linking S13 huntingtin phosphorylation to the pathological properties of mutant huntingtin aggregation, thought to be significant to Huntington’s disease.

[1]  Zhijian J. Chen,et al.  TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections , 2021, Proceedings of the National Academy of Sciences.

[2]  J. Marsh,et al.  Serine residues 13 and 16 are key modulators of mutant huntingtin induced toxicity in Drosophila , 2020, Experimental Neurology.

[3]  M. Hayden,et al.  pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model , 2020, Cell Death & Disease.

[4]  C. Ross,et al.  TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models , 2020, The EMBO journal.

[5]  H. Lashuel,et al.  Site-specific phosphorylation of Huntingtin exon 1 recombinant proteins enabled by the discovery of novel kinases , 2020, bioRxiv.

[6]  D. Lavery,et al.  Ultrasensitive quantitative measurement of huntingtin phosphorylation at residue S13. , 2020, Biochemical and biophysical research communications.

[7]  Jane S. Paulsen,et al.  CAG Repeat Not Polyglutamine Length Determines Timing of Huntington’s Disease Onset , 2019, Cell.

[8]  M. Chesselet,et al.  Phenotype onset in Huntington’s disease knock‐in mice is correlated with the incomplete splicing of the mutant huntingtin gene , 2019, Journal of neuroscience research.

[9]  D. Housman,et al.  IKKβ slows Huntington’s disease progression in R6/1 mice , 2019, Proceedings of the National Academy of Sciences.

[10]  A. Caricasole,et al.  Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease. , 2019, The Journal of clinical investigation.

[11]  P. Holmans,et al.  FAN1 modifies Huntington’s disease progression by stabilizing the expanded HTT CAG repeat , 2018, Human molecular genetics.

[12]  H. Lashuel,et al.  N-terminal Huntingtin (Htt) phosphorylation is a molecular switch regulating Htt aggregation, helical conformation, internalization, and nuclear targeting , 2018, The Journal of Biological Chemistry.

[13]  C. Ross,et al.  N6-Furfuryladenine is protective in Huntington’s disease models by signaling huntingtin phosphorylation , 2018, Proceedings of the National Academy of Sciences.

[14]  N. Gray,et al.  Kinase inhibitors: the road ahead , 2018, Nature Reviews Drug Discovery.

[15]  J. Marsh,et al.  Phosphorylation of huntingtin at residue T3 is decreased in Huntington’s disease and modulates mutant huntingtin protein conformation , 2017, Proceedings of the National Academy of Sciences.

[16]  B. Leavitt,et al.  Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay , 2017, Journal of Huntington's disease.

[17]  K. Fouad,et al.  Disease‐modifying effects of ganglioside GM1 in Huntington's disease models , 2017, EMBO molecular medicine.

[18]  P. Holmans,et al.  A modifier of Huntington's disease onset at the MLH1 locus , 2017, Human molecular genetics.

[19]  P. Holmans,et al.  Genetic modifiers of Mendelian disease: Huntington's disease and the trinucleotide repeat disorders. , 2017, Human molecular genetics.

[20]  J. Marsh,et al.  Polyglutamine expansion affects huntingtin conformation in multiple Huntington’s disease models , 2017, Scientific Reports.

[21]  R. Cole,et al.  Post-Translational Modifications (PTMs), Identified on Endogenous Huntingtin, Cluster within Proteolytic Domains between HEAT Repeats. , 2017, Journal of proteome research.

[22]  F. Giorgini,et al.  Protein phosphatase 1 regulates huntingtin exon 1 aggregation and toxicity , 2017, bioRxiv.

[23]  S. Tabrizi,et al.  The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington’s disease patients , 2017, Scientific Reports.

[24]  S. Finkbeiner,et al.  Serine 421 regulates mutant huntingtin toxicity and clearance in mice. , 2016, The Journal of clinical investigation.

[25]  Wesley R. Legant,et al.  Real-time imaging of Huntingtin aggregates diverting target search and gene transcription , 2016, eLife.

[26]  S. Humbert,et al.  The Biology of Huntingtin , 2016, Neuron.

[27]  A. Caricasole,et al.  Detection of huntingtin exon 1 phosphorylation by Phos-Tag SDS-PAGE: Predominant phosphorylation on threonine 3 and regulation by IKKβ. , 2015, Biochemical and biophysical research communications.

[28]  David J. Arenillas,et al.  A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease , 2015, Nature Neuroscience.

[29]  B. Gerrits,et al.  Scalable Production in Human Cells and Biochemical Characterization of Full-Length Normal and Mutant Huntingtin , 2015, PLoS ONE.

[30]  I. Módy,et al.  N17 Modifies Mutant Huntingtin Nuclear Pathogenesis and Severity of Disease in HD BAC Transgenic Mice , 2015, Neuron.

[31]  A. Caricasole,et al.  Polyglutamine- and Temperature-Dependent Conformational Rigidity in Mutant Huntingtin Revealed by Immunoassays and Circular Dichroism Spectroscopy , 2014, PloS one.

[32]  D. Brunner,et al.  Animal models of Huntington's disease for translation to the clinic: Best practices , 2014, Movement disorders : official journal of the Movement Disorder Society.

[33]  T. Sotnikova,et al.  Dopamine D2 Receptor Relies upon PPM/PP2C Protein Phosphatases to Dephosphorylate Huntingtin Protein* , 2014, The Journal of Biological Chemistry.

[34]  W. E. Rogers,et al.  Probing Kinase Activation and Substrate Specificity with an Engineered Monomeric IKK2 , 2014, Biochemistry.

[35]  H. Lashuel,et al.  One-pot semisynthesis of exon 1 of the Huntingtin protein: new tools for elucidating the role of posttranslational modifications in the pathogenesis of Huntington's disease. , 2014, Angewandte Chemie.

[36]  R. Pappu,et al.  Unmasking the roles of N- and C-terminal flanking sequences from exon 1 of huntingtin as modulators of polyglutamine aggregation , 2013, Proceedings of the National Academy of Sciences.

[37]  D. Housman,et al.  Aberrantly spliced HTT, a new player in Huntington’s disease pathogenesis , 2013, RNA biology.

[38]  L. Mosyak,et al.  Crystal Structure of a Human I kappa B Kinase beta Asymmetric Dimer. , 2013 .

[39]  A. Hoffmann,et al.  A Structural Basis for IκB Kinase 2 Activation Via Oligomerization-Dependent Trans Auto-Phosphorylation , 2013, PLoS biology.

[40]  D. Housman,et al.  Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease , 2013, Proceedings of the National Academy of Sciences.

[41]  M. Diamond,et al.  An N-terminal Nuclear Export Signal Regulates Trafficking and Aggregation of Huntingtin (Htt) Protein Exon 1* , 2013, The Journal of Biological Chemistry.

[42]  R. Truant,et al.  The huntingtin N17 domain is a multifunctional CRM1 and Ran-dependent nuclear and cilial export signal , 2013, Human molecular genetics.

[43]  R. Wetzel,et al.  Serine phosphorylation suppresses huntingtin amyloid accumulation by altering protein aggregation properties. , 2012, Journal of molecular biology.

[44]  S. Tabrizi,et al.  Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. , 2012, The Journal of clinical investigation.

[45]  K. Fouad,et al.  Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice , 2012, Proceedings of the National Academy of Sciences.

[46]  R. Atwal,et al.  Kinase inhibitors modulate huntingtin cell localization and toxicity. , 2011, Nature chemical biology.

[47]  X. W. Yang,et al.  Huntington's disease: flipping a switch on huntingtin. , 2011, Nature chemical biology.

[48]  Jason M. Held,et al.  Mass Spectrometric Identification of Novel Lysine Acetylation Sites in Huntingtin* , 2011, Molecular & Cellular Proteomics.

[49]  L. Havel,et al.  Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. , 2011, Human molecular genetics.

[50]  P. Cohen,et al.  Novel cross-talk within the IKK family controls innate immunity. , 2011, The Biochemical journal.

[51]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[52]  X. W. Yang,et al.  Mouse Models for Validating Preclinical Candidates for Huntington’s Disease , 2011 .

[53]  R. Roos,et al.  Huntington's disease: a clinical review , 2010, Orphanet journal of rare diseases.

[54]  B. Leavitt,et al.  Phosphorylation of Huntingtin at Ser421 in YAC128 Neurons Is Associated with Protection of YAC128 Neurons from NMDA-Mediated Excitotoxicity and Is Modulated by PP1 and PP2A , 2010, The Journal of Neuroscience.

[55]  Andrew F Hill,et al.  Tracking Mutant Huntingtin Aggregation Kinetics in Cells Reveals Three Major Populations That Include an Invariant Oligomer Pool* , 2010, The Journal of Biological Chemistry.

[56]  A. Israël.  The IKK complex, a central regulator of NF-kappaB activation. , 2010, Cold Spring Harbor perspectives in biology.

[57]  S. Finkbeiner,et al.  Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease* , 2010, The Journal of Biological Chemistry.

[58]  S. Finkbeiner,et al.  IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome , 2009, The Journal of cell biology.

[59]  S. Finkbeiner,et al.  Serines 13 and 16 Are Critical Determinants of Full-Length Human Mutant Huntingtin Induced Disease Pathogenesis in HD Mice , 2009, Neuron.

[60]  Yoshiaki Washio,et al.  Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery. , 2009, Current opinion in drug discovery & development.

[61]  Xuhui Huang,et al.  The predicted structure of the headpiece of the Huntingtin protein and its implications on Huntingtin aggregation. , 2009, Journal of molecular biology.

[62]  J. Purcell,et al.  Phosphorylation of Threonine 3 IMPLICATIONS FOR HUNTINGTIN AGGREGATION AND NEUROTOXICITY , 2009 .

[63]  H. Walczak,et al.  Identification of PP2A as a crucial regulator of the NF-κB feedback loop: its inhibition by UVB turns NF-κB into a pro-apoptotic factor , 2008, Cell Death and Differentiation.

[64]  J. Gatot,et al.  Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated? , 2008, Trends in biochemical sciences.

[65]  William A Weiss,et al.  Recognizing and exploiting differences between RNAi and small-molecule inhibitors. , 2007, Nature chemical biology.

[66]  R. Atwal,et al.  Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. , 2007, Human molecular genetics.

[67]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-kappaB and IKK function. , 2007, Nature reviews. Molecular cell biology.

[68]  R. Honkanen,et al.  Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. , 2007, Methods in molecular biology.

[69]  Michael Karin,et al.  Regulation and Function of IKK and IKK-Related Kinases , 2006, Science's STKE.

[70]  Michael P. Cusack,et al.  Huntingtin Phosphorylation Sites Mapped by Mass Spectrometry , 2006, Journal of Biological Chemistry.

[71]  M. MacDonald,et al.  The serum‐ and glucocorticoid‐induced kinase SGK inhibits mutant huntingtin‐induced toxicity by phosphorylating serine 421 of huntingtin , 2004, The European journal of neuroscience.

[72]  P. Patterson,et al.  Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[73]  Guo-Ping Zhou,et al.  Triggering the Interferon Antiviral Response Through an IKK-Related Pathway , 2003, Science.

[74]  G. Bates,et al.  Huntingtin aggregation and toxicity in Huntington's disease , 2003, The Lancet.

[75]  T. Maniatis,et al.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. , 2003, Nature immunology.

[76]  C. Forsyth,et al.  Okadaic acid: the archetypal serine/threonine protein phosphatase inhibitor. , 2002, Current medicinal chemistry.

[77]  Fabrice P Cordelières,et al.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.

[78]  D. Creely,et al.  IKK-i and TBK-1 are Enzymatically Distinct from the Homologous Enzyme IKK-2 , 2002, The Journal of Biological Chemistry.

[79]  S. Ghosh,et al.  Characterization of the Ikappa B-kinase NEMO binding domain. , 2002, The Journal of biological chemistry.

[80]  C. Koboldt,et al.  Characterization of the Recombinant IKK1/IKK2 Heterodimer , 2000, The Journal of Biological Chemistry.

[81]  Shihua Li,et al.  Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. , 1998, Human molecular genetics.

[82]  C A Ross,et al.  Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. , 1998, Human molecular genetics.

[83]  E. Zandi,et al.  The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. , 1997, Cell.

[84]  D B Young,et al.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. , 1997, Science.

[85]  E. Zandi,et al.  A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. , 1997, Nature.

[86]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.